Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 12/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17387706 | 0.90 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1223271 | 0.79 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL20883015 | 0.77 | ADORA2B (0.77) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL4054089 | 0.77 | ADORA2B (0.73) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL4055179 | 0.76 | ADORA2B (0.82) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL25090489 | 0.76 | ADORA2B (0.73) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL19520833 | 0.75 | ADORA2B (0.59) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL4051557 | 0.75 | ADORA2B (0.77) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL29494961 | 0.72 | ADORA2B (1.00) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL4058551 | 0.71 | ADORA2B (0.76) | ADORA2BADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240219394-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-07-04 | — | — | US | claimed |
| EP-4382612-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-06-12 | — | — | EP | claimed |
| WO-2023013791-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | 味の素株式会社 | 2023-02-09 | — | — | WO | claimed |
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | HALOZYME HYPERCON, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12558323-B2 | Particle formation and morphology | ELEKTROFI, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260007615-A1 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | ELEKTROFI INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260000616-A1 | METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATION | ELEKTROFI INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-3908601-B1 | COMPOSITIONS FOR TREATING CANCER | OMEROS CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250383333-A1 | DETERMINATION OF PARTICULATE CONTAMINANTS IN PARTICLES AND COMPOSITIONS | ELEKTROFI INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12433849-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | ELEKTROFI, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250288525-A1 | METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATION | HALOZYME HYPERCON, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20220249663-A1 | METHODS AND COMPOSITIONS FOR CANCER TREATMENT AND TREATMENT SELECTION | APELLIS PHARMACEUTICALS, INC. | 2022-08-11 | — | — | US | disclosed |
| EP-4027989-A1 | METHODS OF TREATING CANCER | Inspirna, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11376255-B2 | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents | iTeos Belgium SA (BE) | 2022-07-05 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2022050230-A1 | COMPOSITION INHIBITING ACTIVATION OF ADENOSINE RECEPTOR | 学校法人埼玉医科大学 | 2022-03-10 | — | — | WO | disclosed |
| WO-2022040246-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | STIMIT CORPORATION (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | OMEROS CORPORATOIN | 2020-11-05 | — | — | US | disclosed |
| WO-2014153424-A1 | REDUCING DIABETES IN PATIENTS RECEIVING HMG-COA REDUCTASE INHIBITORS (STATINS) | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000616-A1 | METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATION | ALB, TNF, TTR | ADORA2B 4301/4885ADORA2A 3439/4885ADORA1 4507/4885 |
| US-11376255-B2 | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents | ADORA2A, ADORA2B, ADORA1 | ADORA2B 2/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | ALB, S100P, S100A8 | ADORA2B 3145/4885ADORA2A 2833/4885ADORA1 2871/4885 |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | ADORA2B 4319/4885ADORA2A 3845/4885ADORA1 4137/4885 |
| US-12558323-B2 | Particle formation and morphology | CD63, EXOSC10, EPCAM | ADORA2B 4009/4885ADORA2A 3001/4885ADORA1 3176/4885 |
| US-20260007615-A1 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | FLNB, FLNA, FUS | ADORA2B 1022/4885ADORA2A 3104/4885ADORA1 2292/4885 |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | LPAR5, LPAR3, LPAR1 | ADORA2B 637/4885ADORA2A 133/4885ADORA1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.